Qtron Investments LLC Sells 1,342 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Qtron Investments LLC reduced its stake in IQVIA Holdings Inc. by 23.9%, selling 1,342 shares, leaving them with 4,274 shares valued at approximately $754,000.
• Following its latest earnings report, IQVIA topped analysts' expectations with an EPS of $2.81, surpassing the consensus estimate of $2.77, while reporting quarterly revenue of $4.02 billion.
• The stock of IQVIA is currently rated as a "Moderate Buy" by analysts, with prices expected to reach a consensus target of $228.62.

Qtron Investments LLC trimmed its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 23.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,274 shares of the medical research company's stock after selling 1,342 shares during the quarter. Qtron Investments LLC's holdings in IQVIA were worth $754,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Continuum Advisory LLC increased its stake in shares of IQVIA by 3.7% in the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after buying an additional 64 shares during the period. Ballentine Partners LLC increased its stake in shares of IQVIA by 4.9% in the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after buying an additional 69 shares during the period. Independent Advisor Alliance increased its stake in shares of IQVIA by 4.2% in the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after buying an additional 72 shares during the period. ST Germain D J Co. Inc. increased its stake in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the period. Finally, Nemes Rush Group LLC increased its stake in shares of IQVIA by 15.0% in the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after buying an additional 81 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Up 3.0%

IQV stock traded up $5.5970 during trading on Friday, hitting $190.9870. 1,619,418 shares of the stock traded hands, compared to its average volume of 1,441,272. The stock has a market cap of $32.47 billion, a price-to-earnings ratio of 27.64, a price-to-earnings-growth ratio of 2.04 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The firm's 50 day moving average is $173.70 and its two-hundred day moving average is $168.51.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the previous year, the company earned $2.64 earnings per share. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research analyst reports. Redburn Partners set a $188.00 price objective on shares of IQVIA in a research report on Friday, May 23rd. Truist Financial boosted their price objective on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. William Blair reissued an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Robert W. Baird upped their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

Insider Activity at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.